You are here

Gynecology

A vaccine that can literally eradicate the majority of cervical cancer cases shows long-term effectiveness in a study published today in The Lancet. This study of 14,215 women in 18 countries extends and solidifies the initial phase 3 efficacy and safety trial of the nine-valent human papilloma virus vaccine, Gardasil 9, that was published in February 2015 in The New England Journal of Medicine.

These new results strengthen the promise that vaccination with Gardasil 9 can reduce 90 percent of cervical cancers.

For young women heading off to college, it can be a time filled with the excitement of living away from home. This new sense of independence should also include taking charge of one's own health, says Dr. Aparna Sridhar, an assistant professor of obstetrics and gynecology at the David Geffen School of Medicine at UCLA.

Gynecologic cancers affect any area of the female reproductive organs (uterus, cervix, ovaries, vulva). For 2017, the American Cancer Society estimates more than 100,000 new cases of gynecologic cancer and more than 31,000 deaths. Luckily these organs are either visible or can give early symptoms of pre-cancer and cancer.

Bottom Line: Women with a history of severe cervical intraepithelial neoplasia, a precancerous condition of the cervix that arises from infection with the human papillomavirus (HPV), had a long-term increased risk of developing anal, vulvar, and vaginal cancer.

Journal in Which the Study was Published: Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Bottom Line: Women with a history of severe cervical intraepithelial neoplasia, a precancerous condition of the cervix that arises from infection with the human papillomavirus (HPV), had a long-term increased risk of developing anal, vulvar, and vaginal cancer.

Journal in Which the Study was Published: Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

A vaccine that can literally eradicate the majority of cervical cancer cases shows long-term effectiveness in a study published today in The Lancet. This study of 14,215 women in 18 countries extends and solidifies the initial phase 3 efficacy and safety trial of the nine-valent human papilloma virus vaccine, Gardasil 9, that was published in February 2015 in The New England Journal of Medicine.

These new results strengthen the promise that vaccination with Gardasil 9 can reduce 90 percent of cervical cancers.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) approved the cobas® HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women 25 and older. The approval follows the March 12 unanimous recommendation from the Microbiology Devices Panel of the FDA's Medical Devices Advisory Committee, making the cobas® HPV Test the first and only HPV test in the United States approved for first-line primary screening.

Results of a study carried out in Brazil showed a strong association between vitamin D deficiency and metabolic syndrome in postmenopausal women. The Metabolic syndrome (MetS), described as a cluster of conditions that heighten the risk of heart disease, stroke and diabetes, is estimated to affect approximately 50% of the female population above the age of 50 in the United States.

Pages

Subscribe to Gynecology